CIS-BUTENEDIOIC ACID,2-Morpholinoethanesulfonic acid,N-Ethylcarbazole

Events & Exhibitions Company News Industry News

Hypoglycemic, but not cause obesity, it may replace the position of metformin
2017-11-06

Recently, a team from the Diabetes Research Center at Columbia University, in collaboration with AstraZeneca and Mount Sinai School of Medicine, published an important article in the international journal Cell together [1], identifying the molecular mechanism by which insulin modulates glucose metabolism and lipid metabolism, they also screened several specific insulin sensitizers, which ca...
Recent research progress in Hepatitis B Drugs and Vaccines
2022-02-15

Hepatitis B is caused by hepatitis B virus (HBV), it can not be cured once infected, and may be converted to chronic hepatitis, cirrhosis and liver cancer. In the treatment of chronic hepatitis B, there are two categories, namely, interferon (common interferon, long-acting interferon) and nucleosides (Lamivudine, Adefovir, Entecavir), but these drugs are unable to cure hepatitis B. To overcome hep...
2017 AASLD Annual Meeting| long-term efficacy of Zepatier
2022-02-15

The 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) was held in Washington, DC, from 20 to 24 October 2017. At the meeting, Merck announced a retrospective data on the long-term efficacy of Zepatier (elbasvir/grazoprevir) in genotype 1 or 4 chronic hepatitis C virus infection in patients with chronic kidney disease. Hepatitis C is a liver disease caused by h...
Forgotten crisis "hepatitis C", is more harmful than hepatitis B
2017-10-18

Hepatitis C and hepatitis B are both caused by the hepatitis virus which can develop into chronic hepatitis, cirrhosis, and even liver cancer. Both of which are globally prevalent (there are currently 257 million hepatitis B patients in the world and 185 million people infected with hepatitis C). Which one is more terrible? Many people will think of hepatitis B, but on the contrary, hepatitis C is...
Synthesis of 3,4-ethylenedioxythiophene (EDOT)
2017-10-17

3,4-ethylenedioxythiophene (EDOT) is not only a stable conductive compound monomer, but also the basic material of conductive skeleton. The polymer PEDOT has the advantages of low energy gap, low electrochemical doping potential, short response time, high color contrast, good stability and so on. It is widely used in various industrial fields. With the deepening of the application of PEDOT, the sy...
NT-proBNP and troponin T, effective way to detect coronary heart disease
2017-10-16

Recently, researchers from Uppsala University have developed a new tool that uses NT-proBNP and troponin T in blood to coronary heart disease and stable coronary heart disease, which makes it possible to give patients with coronary artery disease a more precise and tailor-made treatment. The tool makes it possible to identify those who have the highest risk, in order to achieve preventive treatmen...
Will sodium ion battery replace lithium-ion batteries in the future?
2017-10-13

Lithium-ion battery has been invented for decades, because of high specific energy, high voltage, high efficiency, no self-discharge, no memory effect and many other advantages, it has become the first choice of all industries. However, electrode material resources (lithium) will face a shortage in the future. In order to solve this problem, scientists turn their focus to sodium—the second light m...
Cyclohexylamino buffer family—CHES (103-47-9) and CAPS (1135-40-6)
2022-02-15

In the biochemistry and molecular biology experiments, there is a kind of buffers in alkaline range, which is higher than the commonly used physiological range, that is cyclohexylamino buffer family—2-(Cyclohexylamino)ethanesulfonic acid (CHES) and N-Cyclohexyl-3-aminopropanesulfonic acid (CAPS). Both of which are zwitterionic buffers and are not complexed with metal ions, and are also suitable fo...
The second SGLT-2 inhibitor has been approved in China!
2022-02-15

Recently, CFDA approved the new oral SGLT-2 inhibitor——empagliflozin from Boehringer Ingelheim/Lilly to be listed in China, becoming the second listed SGLT-2 inhibitor in China, for improving glycemic control in patients with type 2 diabetes. The drug can be used as a single drug, combined with metformin or sulfonylurea drugs. Diabetes is a chronic disease, when the pancreas can not produce enough...

<< 21 22 23 24 25 26 27 28 29

>> a total of

pages